Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 May;118(1):21–26. doi: 10.1111/j.1476-5381.1996.tb15361.x

Endothelin-1 and the periaqueductal gray area of the rat: an autoradiographic and functional pharmacological study.

M D'Amico 1, M R Dashwood 1, T D Warner 1
PMCID: PMC1909490  PMID: 8733571

Abstract

Endothelin-1 (ET-1) injected centrally induces pressor effects and associated haemodynamic changes. Here we have evaluated the effects on systemic and regional cardiovascular parameters of injection of ET-1 into the periaqueductal gray (PAG) area of anaesthetized rats. In addition, we have used the ETA receptor-selective antagonist, FR 139317, the ETB receptor-selective antagonist, BQ-788, and the ETA/ ETB receptor non-selective antagonist, SB 209670, to identify the receptor(s) mediating these effects. We have also used in vitro autoradiography to identify binding sites for ET-1 in the PAG. 2. In vitro autoradiography showed dense binding of [125I]-PD 151242 (for ETA receptors) in the PAG area, with the binding sites being homogeneously distributed within the dorsal, lateral and ventral subregions. Tissues incubated with [125I]-BQ 3020 (for ETB receptors) had little binding. 3. Injection of ET-1 (0.1, 1 and 10 pmol per rat) in the dorsolateral PAG area significantly increased, in a dose-dependent manner the mean arterial blood pressure (MAP). The highest dose of ET-1 (10 pmol) also decreased the heart rate by 18 +/- 1%, n = 6 (P < 0.05). Increases in blood pressure induced by ET-1 (1 pmol; 31 +/- 6.6 mmHg, n = 6) were greatly reduced by pre-administration to the PAG area of FR 139317 (5 nmol per rat) or SB 209670 (3 nmol per rat) (97 and 94%, respectively), but were unaffected by BQ-788 (5 nmol per rat). Similarly, FR 139317 and SB 209670 prevented the decrease in heart rate induced by ET-1 while BQ-788 did not affect it. 4. Injection of ET-1 to the PAG area caused falls in renal blood flow (RBF) as measured by an ultrasonic flow probe, and increased renal vascular resistance (RVR). Pre-treatment of the PAG with FR 139317 or SB 209670, but not with BQ-788, prevented this ET-1-induced effect. 5. Injection of ET-1 (10 pmol) also increased total peripheral resistance (TPR; control, 2.39 +/- 0.2 mmHg ml-1 min 100 g body weight) by 100 +/- 9% (n = 5) and reduced the cardiac output (CO; control, 94.7 +/- 3.1 ml min-1) by 30 +/- 3% (n = 5), as determined by radioactive microspheres. Vascular resistances were increased in other organs, such as skeletal muscle (88 +/- 5%, n = 4), the colon (55 +/- 7%, n = 4) and the stomach (47 +/- 3%, n = 4). Pretreatment of the PAG area with FR 139317 or SB 209670 reduced the increases in TPR and vascular resistance, and the reduction in CO caused by ET-1. BQ-788 did not effect the responses to ET-1. 6. Thus, there are predominantly ETA binding sites within the PAG area and injection of ET-1 into the PAG area causes complex haemodynamic changes which are sensitive to ETA receptor antagonism. ETA receptors are, therefore, the predominant mediators of the actions of ET-1 in the PAG of the rat.

Full text

PDF
21

Images in this article

23Figure 1
on p.23
24Figure 3
on p.24

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  2. Beyer M. E., Nerz S., Krämer B. K., Hoffmeister H. M. Hemodynamic and inotropic effects of endothelin-1 in vivo. Basic Res Cardiol. 1994 Jan-Feb;89(1):39–49. doi: 10.1007/BF00788676. [DOI] [PubMed] [Google Scholar]
  3. D'Amico M., Berrino L., Filippelli A., Maione S., Rossi F. Relation between L-arginine-nitric oxide pathway and endothelin-1 effects in periaqueductal gray area of rats. J Cardiovasc Pharmacol. 1994 Dec;24(6):974–978. doi: 10.1097/00005344-199424060-00016. [DOI] [PubMed] [Google Scholar]
  4. D'Amico M., Berrino L., Maione S., Filippelli A., Pizzirusso A., Vitagliano S., Rossi F. Endothelin-1 in rat periaqueductal gray area induces hypertension via glutamatergic receptors. Hypertension. 1995 Apr;25(4 Pt 1):507–510. doi: 10.1161/01.hyp.25.4.507. [DOI] [PubMed] [Google Scholar]
  5. D'Amico M., Warner T. D. Involvement of endothelin in the pressor response following injection of NMDA to the periaqueductal gray area of rats. Br J Pharmacol. 1995 Dec;116(7):2787–2789. doi: 10.1111/j.1476-5381.1995.tb15927.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dashwood M. R., Allen S. P., Luu T. N., Muddle J. R. The effect of the ETA receptor antagonist, FR 139317, on [125I]-ET-1 binding to the atherosclerotic human coronary artery. Br J Pharmacol. 1994 Jun;112(2):386–389. doi: 10.1111/j.1476-5381.1994.tb13083.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fukuroda T., Ozaki S., Ihara M., Ishikawa K., Yano M., Nishikibe M. Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the rabbit pulmonary artery. Br J Pharmacol. 1994 Oct;113(2):336–338. doi: 10.1111/j.1476-5381.1994.tb16901.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hashim M. A., Tadepalli A. S. Hemodynamic responses evoked by endothelin from central cardiovascular neural substrates. Am J Physiol. 1992 Jan;262(1 Pt 2):H1–H9. doi: 10.1152/ajpheart.1992.262.1.H1. [DOI] [PubMed] [Google Scholar]
  9. Ishikawa K., Ihara M., Noguchi K., Mase T., Mino N., Saeki T., Fukuroda T., Fukami T., Ozaki S., Nagase T. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4892–4896. doi: 10.1073/pnas.91.11.4892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Koseki C., Imai M., Hirata Y., Yanagisawa M., Masaki T. Autoradiographic distribution in rat tissues of binding sites for endothelin: a neuropeptide? Am J Physiol. 1989 Apr;256(4 Pt 2):R858–R866. doi: 10.1152/ajpregu.1989.256.4.R858. [DOI] [PubMed] [Google Scholar]
  11. Maione S., Berrino L., Vitagliano S., Leyva J., Rossi F. Interactive role of L-glutamate and vasopressin, at the level of the PAG area, for cardiovascular tone and stereotyped behaviour. Brain Res. 1992 Nov 27;597(1):166–169. doi: 10.1016/0006-8993(92)91521-f. [DOI] [PubMed] [Google Scholar]
  12. McDevitt D. G., Nies A. S. Simultaneous measurement of cardiac output and its distribution with microspheres in the rat. Cardiovasc Res. 1976 Jul;10(4):494–498. doi: 10.1093/cvr/10.4.494. [DOI] [PubMed] [Google Scholar]
  13. Molenaar P., Kuc R. E., Davenport A. P. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart. Br J Pharmacol. 1992 Nov;107(3):637–639. doi: 10.1111/j.1476-5381.1992.tb14498.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Moody C. J., Dashwood M. R., Sykes R. M., Chester M., Jones S. M., Yacoub M. H., Harding S. E. Functional and autoradiographic evidence for endothelin 1 receptors on human and rat cardiac myocytes. Comparison with single smooth muscle cells. Circ Res. 1990 Sep;67(3):764–769. doi: 10.1161/01.res.67.3.764. [DOI] [PubMed] [Google Scholar]
  15. Myers B. D., Moran S. M. Hemodynamically mediated acute renal failure. N Engl J Med. 1986 Jan 9;314(2):97–105. doi: 10.1056/NEJM198601093140207. [DOI] [PubMed] [Google Scholar]
  16. Ohlstein E. H., Nambi P., Douglas S. A., Edwards R. M., Gellai M., Lago A., Leber J. D., Cousins R. D., Gao A., Frazee J. S. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8052–8056. doi: 10.1073/pnas.91.17.8052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rubanyi G. M., Polokoff M. A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994 Sep;46(3):325–415. [PubMed] [Google Scholar]
  18. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  19. Thomas G. R., Thiemermann C., Walder C., Vane J. R. The effects of endothelium-dependent vasodilators on cardiac output and their distribution in the anaesthetized rat: a comparison with sodium nitroprusside. Br J Pharmacol. 1988 Nov;95(3):986–992. doi: 10.1111/j.1476-5381.1988.tb11729.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Warner T. D., Allcock G. H., Corder R., Vane J. R. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol. 1993 Oct;110(2):777–782. doi: 10.1111/j.1476-5381.1993.tb13879.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES